Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma

RenJi Hospital · 2023
ClinicalTrials.gov · Datasets · License: Public Domain · 2023
Open Source ↗
firstline
non-clear renal cell carcinoma, fruquintinib, serplulimab, combination therapy, first-line, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 800388
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.